Gregory Oakes

Chief Executive Officer, Slate Medicines

Appears in 1 story

Last updated Aug 18, 2026

Stories

Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Money Moves

As of August 2026: Set to lead the combined public company

Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal backed by a $245 million private placement.

Updated Aug 18